Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis Deal

Apellis surges after Biogen's $5.6 billion buyout at $41 per share, adding complement therapies and boosting long-term EPS outlook. Importance Rank: 1 read more

Go to News Site